We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ligand Pharmaceuticals Incorporated | NASDAQ:LGND | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.07 | -1.45% | 72.83 | 72.19 | 75.73 | 74.70 | 72.61 | 74.05 | 114,789 | 01:00:00 |
Delaware | 001-33093 | 77-0160744 | ||||||
(State or other jurisdiction of | (Commission File Number) | (I.R.S. Employer | ||||||
incorporation or organization) | Identification No.) |
3911 Sorrento Valley Boulevard, Suite 110 | ||||||||
San Diego | ||||||||
CA | 92121 | |||||||
(Address of principal executive offices) | (Zip Code) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Common Stock, par value $0.001 per share | LGND | The Nasdaq Global Market |
LIGAND PHARMACEUTICALS INCORPORATED | |||||
Date: September 23, 2020 |
By: /s/ Charles S. Berkman
Name: Charles S. Berkman
Title: Senior Vice President, General Counsel and Secretary
|
1 Year Ligand Pharmaceuticals Chart |
1 Month Ligand Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions